Filter
100
Text search:
Corbett,
E.
L.
Featured
11
12
Language
Document type
73
14
10
1
1
1
Countries / Regions
4
4
4
3
3
3
3
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
24
4
4
3
2
1
Toolboxes
43
15
5
4
3
3
3
2
1
1
1
1
1.HIV infections – drug therapy. 2.Anti-HIV agents – adverse effects. 3.Anti-retroviral agents. 4.Benzoxazines – adverse effects. 5.Pregnancy. 6.Disease transmission, Vertical - prevention and control. 7.Treatment outcome. I.World Health Organization
Policy statement.
Guidelines for national programmes and other stakeholders
世界卫生组织 结核菌/艾滋病病毒双 重感染防治政策指南
——适用于国家规划 和利益攸关方
Key population brief.
Краткое руководство.
Best practice guidelines are systematically developed statements designed to assist nurses working in partnership with persons and their families to make decisions about health care and services (Field & Lohr, 1990). This nursing Best Practice Guideline (BPG) is intended to replace the RNAO BPGs Scr
...
COVID-19 vaccine hesitancy is currently one of the main obstacles to worldwide herd immunity and socioeconomic recovery. Because vaccine coverage can vary between and within countries, it is important
to identify sources of variation so that policies can be tailored to different population groups.
...
Offering additional pre-exposure prophylaxis (PrEP) choices has the potential to increase uptake and effective use of PrEP, and of HIV prevention overall, as it allows people to choose a method that they prefer.
In this guideline, WHO recommends an offering long-acting injectable lenacapavir (LEN
...
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex B
Alto a la Tuberculosis.
Enfermedades Transmisibles.
Sub-Saharan African Journal of Medicine: Year : 2014 | Volume : 1 | Issue : 1 | Page : 1-14
Pharmaceutical profile of DRC
